Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 416,182 Shares

Key Points

• Eric Venker, CEO of Roivant Sciences, sold 416,182 shares at an average price of $14.99, totaling over $6.2 million, reducing his ownership by 16.44%.
• Roivant Sciences stocks have seen a decline, trading at $14.74, while analysts have given the stock an average price target of $19.94 with a consensus rating of "Buy."
• Institutional investors have increased their stakes in Roivant Sciences, with significant growth reported by firms such as Parallel Advisors and CWM LLC during recent quarters.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 416,182 shares of the firm's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $14.99, for a total value of $6,238,568.18. Following the transaction, the chief executive officer owned 2,115,959 shares in the company, valued at approximately $31,718,225.41. This trade represents a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Tuesday, September 23rd, Eric Venker sold 611,000 shares of Roivant Sciences stock. The shares were sold at an average price of $14.83, for a total value of $9,061,130.00.
• On Friday, September 19th, Eric Venker sold 683,818 shares of Roivant Sciences stock. The stock was sold at an average price of $14.95, for a total value of $10,223,079.10.
• On Wednesday, August 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.72, for a total value of $1,172,000.00.
• On Monday, July 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded down $0.20 during trading on Tuesday, reaching $14.74. The company's stock had a trading volume of 8,043,594 shares, compared to its average volume of 8,748,874. The business's fifty day moving average price is $12.35 and its 200-day moving average price is $11.34. The firm has a market cap of $10.07 billion, a price-to-earnings ratio of -21.06 and a beta of 1.15. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $16.05.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Parallel Advisors LLC increased its stake in Roivant Sciences by 80.5% during the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company's stock valued at $25,000 after acquiring an additional 1,108 shares during the period. CWM LLC grew its stake in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company's stock valued at $34,000 after purchasing an additional 920 shares during the period. UMB Bank n.a. grew its stake in shares of Roivant Sciences by 112.7% in the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company's stock valued at $42,000 after purchasing an additional 2,195 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Roivant Sciences by 94.8% in the 1st quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company's stock valued at $46,000 after purchasing an additional 2,233 shares during the period. Finally, Fifth Third Bancorp grew its stake in shares of Roivant Sciences by 59.3% in the 1st quarter. Fifth Third Bancorp now owns 5,118 shares of the company's stock valued at $52,000 after purchasing an additional 1,905 shares during the period. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ROIV has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price objective on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, September 18th. Leerink Partners lifted their price objective on Roivant Sciences from $18.00 to $22.00 and gave the stock an "outperform" rating in a research note on Thursday, September 18th. Guggenheim lifted their price objective on Roivant Sciences from $15.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, September 18th. HC Wainwright boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. Finally, The Goldman Sachs Group boosted their price target on Roivant Sciences from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of "Buy" and an average price target of $19.94.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.